Search for content, post, videos

Orion and MSD announce global collaboration

Orion Corporation and MSD have announced a global development and commercialisation agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.